Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 11

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 11
---
 Parkinson’s disease. In addition, we plan to continue to advance our existing research programs and initiate additional programs targeting allosteric binding sites identified with the Magellan™ platform in various therapeutic areas through discovery collaborations with industry partners and academic institutions.

<div align='center'>S-5</div>

TABLE OF CONTENTS

<div align='center'>Our Product Pipeline</div>

#### Corporate Information
We were incorporated under the laws of the state of Delaware on June 26, 2020 under the name Gain Therapeutics, Inc. Our principal executive offices are located at 4800 Montgomery Lane, Suite 220, Bethesda, MD 20814. Our telephone number is (301) 500-1556. Our website address is http://www.gaintherapeutics.com. Information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus.

<div align='center'>S-6</div>

TABLE OF CONTENTS

### THE OFFERING

#### Issuer
Gain Therapeutics, Inc.

Common stock offered by us pursuant to this prospectus supplement

shares of common stock.

Pre-Funded Warrants offered by us pursuant to this prospectus supplement

We are offering Pre-Funded Warrants to purchase up to an aggregate of shares of common stock in lieu of shares of common stock, to those purchasers whose purchase of shares of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock following the consummation of this offering. A holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with its affiliates and certain related parties, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. The Pre-Funded Warrants will be exercisable upon issuance at an exercise price of $0.0001 per share of Common Stock and will expire when exercised in full. For more information, see the section titled “Description of Securities We Are Offering — Pre-Funded Warrants.” This prospectus supplement also relates to the offering of the shares of common